These first-generation TK inhibitors (TKIs) were found to be effective in the treatment of advanced non-small-cell lung cancer (NSCLC) in somatic activating mutations (Martinez-Marti et al., 2019). The gene discussed is TKT; the disease is non-small cell lung carcinoma.